AJR InPractice
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Partridge, S. C.
Right arrow Articles by Hylton, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Partridge, S. C.
Right arrow Articles by Hylton, N. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
AJR 2005; 184:1774-1781
© American Roentgen Ray Society

MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival

Savannah C. Partridge1,2, Jessica E. Gibbs1, Ying Lu1, Laura J. Esserman3, Debasish Tripathy4, Dulcy S. Wolverton1, Hope S. Rugo5, E. Shelley Hwang3, Cheryl A. Ewing3 and Nola M. Hylton1

1 Department of Radiology, University of California, San Francisco, San Francisco, CA 94143.
3 Department of Surgery, University of California, San Francisco, San Francisco, CA 94143.
4 Department of Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
5 Department of Oncology, University of California, San Francisco, San Francisco, CA 94143.

OBJECTIVE. The purpose of this study was to assess the value of MRI measurements of breast tumor size for predicting recurrence-free survival (RFS) in patients undergoing neoadjuvant (preoperative) chemotherapy and to compare the predictive value of MRI with that of established prognostic indicators.

SUBJECTS AND METHODS. The study included 62 patients undergoing neoadjuvant chemotherapy. The longest diameter and volume of each tumor were measured on MRI before and after one and four cycles of treatment. Change in diameter on clinical examination, tumor size at pathology, and the number of positive nodes were determined. Each measure of tumor extent was assessed for the ability to predict RFS.

RESULTS. Univariate Cox analysis showed initial MRI volume was the strongest predictor of RFS (p = 0.002). Final change in MRI volume (p = 0.015) was more predictive than change in diameter on MRI (p = 0.077) or clinical examination (p = 0.27). Initial diameter on MRI (p = 0.003) and clinical examination (p = 0.033), tumor size at pathology (p = 0.016), and number of positive nodes (p = 0.045) were also significantly predictive of RFS. Early change in MRI volume (p = 0.071) and diameter (p = 0.081) after one chemotherapy cycle showed trends of association with RFS. Multivariate analysis showed initial MRI volume (p = 0.005) and final change in MRI volume (p = 0.003) were significant independent predictors.

CONCLUSION. MRI tumor volume was more predictive of RFS than tumor diameter, suggesting that volumetric changes measured using MRI may provide a more sensitive assessment of treatment efficacy.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
RadiologyHome page
S. Jiang, B. W. Pogue, C. M. Carpenter, S. P. Poplack, W. A. Wells, C. A. Kogel, J. A. Forero, L. S. Muffly, G. N. Schwartz, K. D. Paulsen, et al.
Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy with Tomographic Diffuse Optical Spectroscopy: Case Studies of Tumor Region-of-Interest Changes
Radiology, August 1, 2009; 252(2): 551 - 560.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
H. Elsamaloty, M. S. Elzawawi, S. Mohammad, and N. Herial
Increasing Accuracy of Detection of Breast Cancer with 3-T MRI
Am. J. Roentgenol., April 1, 2009; 192(4): 1142 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
C. E. Loo, H. J. Teertstra, S. Rodenhuis, M. J. van de Vijver, J. Hannemann, S. H. Muller, M.-J. V. Peeters, and K. G. A. Gilhuijs
Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results
Am. J. Roentgenol., November 1, 2008; 191(5): 1331 - 1338.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
K.-L. Li, S. C. Partridge, B. N. Joe, J. E. Gibbs, Y. Lu, L. J. Esserman, and N. M. Hylton
Invasive Breast Cancer: Predicting Disease Recurrence by Using High-Spatial-Resolution Signal Enhancement Ratio Imaging
Radiology, July 1, 2008; 248(1): 79 - 87.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. Hattangadi, C. Park, J. Rembert, C. Klifa, J. Hwang, J. Gibbs, and N. Hylton
Breast Stromal Enhancement on MRI Is Associated with Response to Neoadjuvant Chemotherapy
Am. J. Roentgenol., June 1, 2008; 190(6): 1630 - 1636.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al.
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. J. Solin, S. G. Orel, W.-T. Hwang, E. E. Harris, and M. D. Schnall
Relationship of Breast Magnetic Resonance Imaging to Outcome After Breast-Conservation Treatment With Radiation for Women With Early-Stage Invasive Breast Carcinoma or Ductal Carcinoma in Situ
J. Clin. Oncol., January 20, 2008; 26(3): 386 - 391.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Roentgen Ray Society.